logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Lorna Helen Mitchell

USPTO Granted Patents = 33 

 

 

Average Co-Inventor Count = 4.5

ph-index = 16

Forward Citations = 632(Granted Patents)


Company Filing History:

goldMedal33 out of 158 
 
Epizyme, Inc.
 patents

Years Active: 2015-2022

Loading Chart...
Loading Chart...
Loading Chart...
33 patents (USPTO):Explore Patents
1. 11512053 - Arginine methyltransferase inhibitors and uses thereof (2022-11-29),
2. 11185531 - Arginine methyltransferase inhibitors and uses thereof (2021-11-30),
3. 10800743 - Arginine methyltransferase inhibitors and uses thereof (2020-10-13),
4. 10669243 - Isoxazole carboxamides as irreversible SMYD inhibitors (2020-06-02),
5. 10632103 - Arginine methyltransferase inhibitors and uses thereof (2020-04-28),
6. 10577363 - Substituted piperidine compounds (2020-03-03),
7. 10428029 - Isoxazole carboxamide compounds (2019-10-01),
8. 10266526 - Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer (2019-04-23),
9. 10227307 - PRMT1 inhibitors and uses thereof (2019-03-12),
10. 10179773 - Isoxazole carboxamides as irreversible SMYD inhibitors (2019-01-15),
11. 10106510 - Substituted isoxazoles for treating cancer (2018-10-23),
12. 10081603 - Arginine methyltransferase inhibitors and uses thereof (2018-09-25),
13. 10039748 - PRMT1 inhibitors and uses thereof (2018-08-07),
14. 9943504 - Arginine methyltransferase inhibitors and uses thereof (2018-04-17),
15. 9868703 - PRMT1 inhibitors and uses thereof (2018-01-16),

Title: Lorna Helen Mitchell: Innovator in Methyltransferase Research

Introduction

Lorna Helen Mitchell is a prominent inventor based in Cambridge, MA, recognized for her significant contributions to the field of biochemistry and pharmaceuticals. With an impressive portfolio of 33 patents, her work primarily focuses on developing innovative compounds aimed at treating disorders linked to arginine methyltransferase activity.

Latest Patents

Among her latest patents, Lorna has developed compounds described as arginine methyltransferase inhibitors. These compounds, outlined by specific formulas, are designed to inhibit arginine methyltransferase activity effectively. The patents detail both the synthetic process and pharmaceutical compositions of these compounds, emphasizing their utility in treating ailments that involve arginine methyltransferase-mediated disorders.

Career Highlights

Lorna currently works with Epizyme, Inc., a biotechnology company that specializes in developing innovative therapies for cancer and other diseases. Her tenure at Epizyme has been marked by the successful advancement of her research into practical medical applications, further solidifying her reputation as a leader in her field.

Collaborations

Throughout her career, Lorna has collaborated with notable colleagues, including Richard Chesworth and Gideon Shapiro. Their combined expertise has been instrumental in enhancing the quality of research and innovation within the organization and beyond.

Conclusion

Lorna Helen Mitchell's work exemplifies the impact of innovative research in developing therapeutic solutions for complex health challenges. With a strong foundation of patents and collaborative efforts, she continues to make strides in the realm of pharmaceutical innovation, paving the way for future advancements in treatment strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…